Carol Lim

Title: Carol Lim: Innovator in Polynucleotide Decoys

Introduction

Carol Lim is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of polynucleotide decoys that inhibit MHC-II expression. With a total of 2 patents, her work is paving the way for innovative treatments in immunology and virology.

Latest Patents

One of her latest patents focuses on a newly discovered class of polynucleotide decoys that competitively inhibit the binding of transcription factors to the X-box sequence. This binding is essential for the expression of MHC-II genes. The invention outlines methods for preparing these decoys and their applications. Specifically, these polynucleotide decoys mimic the X-Box of MHC-II and bind competitively to the MHC-II transcription factor RF-X. This interaction modulates MHC-II antigen expression, which can inhibit the expression of HLA molecules on donor cells or organs. This renders them invisible to the host's immune system, providing potential treatments for autoimmune diseases characterized by dysfunctional MHC class II antigen expression. Additionally, due to RF-X's role in the expression of several viral proteins, these decoys can also be utilized in treating individuals infected with hepatitis B virus or cytomegalovirus.

Career Highlights

Carol Lim is affiliated with the University of California, where she continues her research and innovation in biotechnology. Her work has garnered attention for its potential applications in medical treatments and therapies.

Collaborations

Some of her notable coworkers include C Anthony Hunt and Marvin R Garovoy, who contribute to her research endeavors and collaborative projects.

Conclusion

Carol Lim's innovative work in the field of polynucleotide decoys represents a significant advancement in biotechnology. Her contributions have the potential to transform treatment approaches for various autoimmune diseases and viral infections.